Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 10Urogenital Neoplasms 1Renal Insufficiency 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Neoplasms by Site 1Neoplasms 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Genital Neoplasms, Male 1Genital Diseases, Male 1

Interventions

Abiraterone Acetate 3Paclitaxel 2sipuleucel-T 1rucaparib 1onapristone 1olaparib 1niraparib 1luprolide acetate gel depot 1gallium 68 PSMA-11 1apalutamide 1abiraterone 1Suspensions 1Powders 1Pluvicto 1Leuprolide 1Imatinib Mesylate 1EPI-506 1BAY 86-7548 1Androgen Antagonists 1Adrenal Cortex Hormones 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Genital Neoplasms, Male × gallium 68 PSMA-11 × Clear all
NCT04597411 2026-04-30

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Endocyte

Phase 1 Active not recruiting
101 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡